Next-Generation-Sequencing Approach to Neutropenic Sepsis
Recruiting now
Conditions studied: Febrile Neutropenia
In brief
The aim of this prospective, observational, non-interventional, multi-centre study of the diagnostic use of DISQVER in neutropenic patients with FN is to provide further evidence of the efficacy of an NGS-based approach for detecting bloodstream infection in neutropenic patients.
Key facts
- Study ID
- NCT05815628
- Run by
- Boris Böll
- People needed
- 400
- Starts
- 2024-06-05
- Expected to finish
- 2026-11-01
- Last updated by the study team
- 2025-08-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥18 years
- Informed consent
- Neutropenia defined as <500 ANC (Absolute neutrophil Count)/µl or <1000 WBC (White bloddcell Count)/µl if ANC is not available
- Fever (with an onset < 24h) or Sepsis (with an onset <24h) Patients with a life-threatening - organ dysfunction caused by a dysregulated host response to a suspected or proven infection.
You may not qualify if…
- Age < 18 years
- Refusal or inability to give consent Inability to give informed consent if no acceptable patient representative is available
- Patients who had previously been included, but develop a new episode of fever during the same hospitalization, will not be included a second time
- Death is deemed imminent and inevitable
Where it is running
- University Hospital of Cologne — Cologne, Germany (enrolling)
- Hospital Dessau — Dessau, Germany (enrolling)
- University Hospital of Essen — Essen, Germany (enrolling)
- University Hospital of Frankfurt — Frankfurt am Main, Germany (enrolling)
- University Hospital of Leipzig — Leipzig, Germany (enrolling)
- University Hospital of Magdeburg — Magdeburg, Germany (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.